{
    "symbol": "PBLA",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-16 19:49:03",
    "content": " To recap the milestones as we continue to execute our development programs, we anticipate the opening of a non-small cell lung cancer STK11 mutation Phase I trial, the AACR poster presentation of the ovarian preclinical work, a futility analysis for the SWOG colon cancer risk reduction trial in the first half of this year, the opening of the neoadjuvant trial in ovarian cancer trial, the Phase III FAP trial to open in the second half of this year, Phase I non-small cell lung cancer data in the second half of this year which will inform the Phase II portion of the non-small cell lung cancer trial, which we hope to open by year end, final data from the Phase I programs in first-line metastatic pancreatic cancer and early onset Type 1 diabetes, and finally, the interim analysis of the ASPIRE trial in early 2024."
}